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ABSTRACT
Colorectal cancer (CRC) is the third most common cancer and a leading cause
of cancer-related mortality. Observed during CRC tumorigenesis is loss of posttranscriptional regulation of tumor-promoting genes such as COX-2, TNFα and
VEGF. Overexpression of the RNA-binding protein HuR (ELAVL1) occurs during
colon tumorigenesis and is abnormally present within the cytoplasm, where it posttranscriptionally regulates genes through its interaction with 3'UTR AU-rich elements
(AREs). Here, we examine the therapeutic potential of targeting HuR using MS-444, a
small molecule HuR inhibitor. Treatment of CRC cells with MS-444 resulted in growth
inhibition and increased apoptotic gene expression, while similar treatment doses
in non-transformed intestinal cells had no appreciable effects. Mechanistically, MS444 disrupted HuR cytoplasmic trafficking and released ARE-mRNAs for localization
to P-bodies, but did not affect total HuR expression levels. This resulted in MS-444mediated inhibition of COX-2 and other ARE-mRNA expression levels. Importantly, MS444 was well tolerated and inhibited xenograft CRC tumor growth through enhanced
apoptosis and decreased angiogenesis upon intraperitoneal administration. In vivo
treatment of MS-444 inhibited HuR cytoplasmic localization and decreased COX-2
expression in tumors. These findings provide evidence that therapeutic strategies to
target HuR in CRC warrant further investigation in an effort to move this approach
to the clinic.

inflammation. For instance, in normal intestinal epithelium,
levels of pro-oncogenic factors are controlled through 3'UTR AU-rich elements (AREs) that target mRNAs for
rapid turnover, a process known as ARE-mediated mRNA
decay [2]. However, this mechanism of gene regulation
is compromised during colorectal tumorigenesis, thereby
allowing for selective overexpression of tumor promoting
factors such as COX-2 [3–6].

INTRODUCTION
The lifetime risk of developing colorectal (CRC)
cancer is ~5% for both men and women in the USA [1].
Various genetic alterations have been identified that promote
the initiation and progression of colon tumorigenesis.
Facilitating this process is the dysregulation of gene
regulatory mechanisms that can modulate cell growth and
www.impactjournals.com/oncotarget
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A key factor that mediates ARE-mRNA stability
is HuR (ELAVL1), which is a member of a family of
proteins analogous to the Drosophila embryonic-lethal
abnormal vision (ELAV) proteins [7]. HuR has been
previously shown to bind to its targets via ARE motifs
and promote increased mRNA stability [8–10]. In normal
intestinal epithelium, HuR is localized predominantly
in the nucleus (>90%) and can shuttle between the
nucleus and cytoplasm [4, 8, 11, 12]. However, HuR
overexpression and cytoplasmic localization is observed
in 76% of colorectal adenomas and 94% of colorectal
adenocarcinomas [12], allowing for aberrant stabilization
of ARE-containing oncogenic mRNAs.
Previous work has identified HuR as a central protein
in the process of tumorigenesis. HuR has been shown to
increase cell division by enhancing the stability of several
mRNAs that regulate growth and proliferation, such as
cyclin A, cyclin B1 and c-fos [13, 14]. Additionally, HuR
regulates key carcinogenic processes via its stabilization
of the pro-inflammatory and angiogenic factors such as
TNF-α, COX-2, and VEGF, among others [4, 10, 12, 15,
16]. Through its pleiotropic effects on tumor-promoting
gene expression, CRC tumor-derived HuR can be viewed
as a central node in promoting pathogenic gene expression
necessary for the various hallmarks of cancer [7, 17].
In light of its central role in tumorigenesis and its
differential expression between normal and cancerous
tissues, HuR has emerged as an attractive therapeutic
target for cancer [18–20]. Efforts to identify novel HuR
inhibitors have led to the discovery of small molecule
compounds derived from microbial and plant extracts,
among them MS-444 [21]. Interestingly, MS-444
was shown to interfere with HuR binding to its target
mRNAs and influence HuR cytoplasmic localization.
Such properties resulted in growth inhibition and loss of
cytokine expression in inflammatory cell models [21].
In this report, we demonstrate that cytoplasmic HuR
localization sensitizes colon cancer cells to the growthinhibitory effects of MS-444, while non-transformed
intestinal epithelial cells are refractory to these effects.
Additionally, we demonstrate that HuR inhibition by MS444 results in inhibition of COX-2 expression both in vitro
and in vivo. Importantly, MS-444 efficiently inhibited
CRC tumor growth in pre-clinical models, thereby
underscoring HuR inhibition as a viable and cancer cellspecific therapeutic strategy.

as myosin light chain (MLC) kinase inhibitor [22, 23].
Molecular docking between the conserved tandem RNA
recognition motif (RRM) domains 1 and 2 that are
responsible for ARE-binding activity [24–28] and MS-444
predicted a binding energy of -4.6 kcal/mol with hydrogen
bonding within the RRM2 domain at residues Ser146 and
Met117 with bond lengths of 2.7 Å and 2.5 Å, respectively
(Figure 1A). This possible binding mode is consistent with
previous data showing that MS-444 inhibits an RRM1-2
truncation mutant of HuR [21].
To determine the effects of inhibiting HuR by
MS-444, CRC cells that display HuR overexpression
(HCT116, HCA-7, RKO, HT-29, and SW480) [3, 4, 12,
29, 30] were treated with various concentrations (1–100
μM) of MS-444 for 48 hr. Growth inhibition was observed
in all CRC lines with IC50 values ranging from 5.60 μM
to 14.21 μM with observable effects seen at 10 μM MS444 (Figure 1B-1C). Contrasting effects were observed
using non-transformed small intestinal (RIE-1) and
colonic (YAMC) epithelial cells [31]. Both cell types
display properties of normal intestinal epithelial cells (e.g.
polarized growth, formation of tight adherens junctions,
and contact-mediated growth inhibition) and are proficient
in ARE-mRNA decay [32–34]. Both non-transformed
cell lines were ~3- to 4-fold less responsive to MS-444mediated growth inhibition, with IC50 values of 40.70
μM and 28.16 μM (P < 0.05) (Figure 1B). Additionally,
examination of nuclear morphology by Hoechst staining
showed MS-444-treated CRC cells displayed apoptotic
features, such as fragmented and condensed chromatin,
while RIE-1 nuclei remained intact in the presence of MS444 (Figure 1C).
Previous studies have demonstrated HuR
overexpression to be anti-apoptotic through its influence
on the expression of multiple pro-survival mRNAs
[35, 36]. To determine if HuR inhibition by MS-444
promoted apoptosis, HCT116 colon cancer cells and
non-transformed RIE-1 cells were treated with 10 μM
MS-444 for 48 hr and assayed by flow cytometry for
annexin V detection using propidium iodide to identify
and exclude late apoptotic and necrotic cells. Treatment
of cells with cycloheximide and TNF-α served as a
positive control. While MS-444 treatment triggered a
strong (>5-fold) apoptotic response in HCT116 cells, RIE1 cells were refractory to this effect at identical MS-444
concentrations (Figure 2A-2B). Similar to these results,
MS-444 treatment promoted caspase 3 activation in CRC
cells HCT116 and HCA-7 with no detectable levels of
caspase 3 cleavage observed in RIE-1 cells (Figure 2C).
A significant increase in pro-apoptotic gene expression
was observed in MS-444-treated SW480 and HCT116
CRC cells (Figure 2D and data not shown, respectively).
Previous studies have demonstrated that siRNA-mediated
knockdown of HuR can promote apoptosis [35, 36].
Consistent with this, siRNA knockdown of HuR in
HCT116 cells resulted in apoptosis. However, apoptosis

RESULTS
MS-444 inhibits the growth of CRC cells
A high-throughput based biochemical screen had
previously identified the chrysanthone-like compound
MS-444 (Figure 1A) as a specific inhibitor of HuR binding
of ARE-RNAs [21]. MS-444 is produced by gram-positive
bacteria Micromonospora and originally characterized
www.impactjournals.com/oncotarget
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Figure 1: MS-444 inhibits colorectal cancer cell proliferation. A. MS-444 structure and molecular docking with HuR RRM1/2

(PDB ID: 4EGL). B. Human colorectal cancer cell lines RKO, HCA-7, and HCT116, HT-29, and SW480 and the non-transformed intestinal
epithelial cell lines RIE-1 and YAMC were treated with varying concentrations of MS-444 for 48 hr. Cell survival was measured by MTT
assay after incubation of cells for 48 hr with MS-444. Relative cell survival was calculated as percentage normalized to DMSO vehicletreated cells and plotted to determine IC50. Data is represented as average of 4 independent experiments ± SEM. C. RKO, HCA-7, HCT116
and RIE-1 cells were treated with 10 μM MS-444 or vehicle control for 48 hr and subjected to phase contrast microscopy and 1 μg/ml
Hoechst 33342 staining to visualize cellular and nuclear morphology, respectively. Bars = 10 μm.
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Figure 2: MS-444 selectively promotes apoptosis in CRC cells. A-B. HCT116 and RIE-1 cells were treated with 10 μM MS-444

for 48 hr and stained Annexin V-FITC and PI to detect apoptotic cell death. Cells treated with 5 μg/ml cycloheximide and 10 ng/ml TNF-α
for 8 hr were used as positive controls. Flow cytometry analysis was done to determine the percentage of Annexin V-positive cells. Bar
graphs representing the observed percentages of Annexin-V-positive cells with percentages shown as averages of 3 experiments ± SEM. C.
RIE-1, HCT116, and HCA-7 cells were treated with 10 μM MS-444 for 48 hr and detected for cleaved caspase 3 by western blot. Actin was
used as a loading control. D. SW480 cells treated with 10 μM MS-444 for 48 hr were subjected to a qPCR apoptosis array. Genes induced
>1.5-fold are shown as fold change relative to control-treated cells and are the average of 3 experiments.
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induction by HuR knockdown was less robust (15.5%)
when compared to 10 μM MS-444 treatment (41.3%)
(Supplementary Figure S1A-S1B, Figure 1A-1B).
Together, these results demonstrate the ability of MS-444
to promote apoptosis selectively in CRC cancer cells and
not in non-transformed intestinal epithelial cells within
the low micromolar concentration range, thus providing a
potential therapeutic window.

as compared to 31.93 μM in non-transformed cells (Figure
3D). Similar results were obtained using conditionally
immortalized YAMC colonocytes and Ras-transformed
YAMC cells expressing the v-Ha-Ras oncogene [39]
(YAMC-Ras, Figure 3E-3F), further indicating that MS444 sensitivity correlates with cytoplasmic HuR.

MS-444 regulates COX-2 expression in
CRC cells

Cytoplasmic localization of HuR sensitizes
cells to MS-444

Our prior work has shown HuR to be a key
contributor to COX-2 overexpression in CRC through
ARE-mediated mRNA stabilization [3, 6, 12]. To test
whether HuR inhibition by MS-444 affected endogenous
COX-2 levels, HCA-7 cells were treated with 12 μM MS444 over a 24 hr time-course that revealed a loss of COX2 mRNA occurring within 6-12 hr of treatment (Figure
4A). HCA-7 cells were then treated with increasing
concentrations of MS-444 for 8 hr, and COX-2 mRNA and
protein expression was assayed. COX-2 mRNA expression
was significantly inhibited in a dose-dependent manner
with an IC50 of 6.75 μM (Figure 4B), along with a similar
dose-dependent attenuation in COX-2 protein observed
(Figure 4C).
To establish whether the effect of MS-444 on
COX-2 expression occurred through disruption of the
HuR/COX-2 mRNA association, ribonucleoprotein
immunoprecipitation (RNP-IP) was performed in
HCA-7 cells treated with 10 μM MS-444 for 6 hr and
immunoprecipitation of cytoplasmic lysates was done
using an antibody against HuR. The association of COX-2
mRNA with HuR was assayed by qPCR of COX-2 mRNA
in immunoprecipitates. As shown in Figure 4D, COX-2
mRNA was significantly enriched in the HuR IP samples
in vehicle treated cells compared to RNP-IP samples
using control IgG. In contrast, a 4-fold reduction in COX2 mRNA was observed in HuR immunoprecipitates from
MS-444 treated cells. To determine if the effects on COX2 occurred via the ARE-containing COX-2 3'UTR [10],
HCT116 cells were transfected with luciferase reporter
containing the COX-2 3’UTR and treated with 10 μM MS444 for 8 hr (Figure 4E), MS-444 promoted approximately
2-fold inhibition in luciferase expression in the presence
of the ARE-containing 3'UTR and did not significantly
influence expression of a control reporter (LucΔ3'UTR).
Consistent with these observations, MS-444 did not
impact levels of non-ARE-containing mRNAs COX-1 and
β-actin (Supplementary Figure S4A), further supporting
that MS-444 regulates COX-2 expression via the 3’UTR.
In non-transformed intestinal epithelial cells, COX2 and ARE-mRNAs are degraded in discrete cytoplasmic
RNA granules known as processing bodies (P-bodies)
[31]. To determine the effects of MS-444 upon P-body
formation and mRNA localization to P-bodies, we
utilized the MS2 dual plasmid system for fluorescent RNA
visualization [31, 40]. HCT116 cells were transfected

Rapid ARE-mRNA decay occurs primarily in the
cytoplasm, however the presence of cytoplasmic HuR
in CRC cells impedes this process [3, 4, 6, 12, 37, 38].
To test the effects of MS-444 on HuR behavior in CRC
cells, immunofluorescence and western blot analyses of
HuR expression revealed that 10 μM MS-444 induced
nuclear HuR localization in HCT116 cells with loss of
cytoplasmic HuR occurring after 1 hr of treatment (Figure
3A-3B). This rapid change in localization was not due to
HuR loss since treatment with 10 and 50 μM MS-444 up
to 24 hr showed no differences in level of HuR expression
in whole cell lysates (Figure 3B, Supplementary Figure
S3A) and HuR cleavage products were not observed (data
not shown). The effects of MS-444 also were specific to
HuR since subcellular localization of endogenous (p38
MAPK, Erk1/2, and Akt) proteins were not impacted
(Supplementary Figure S2). Furthermore, MS-444
was not observed to impact myosin light chain (MLC)
kinase levels [22, 23] or MAPK signaling up to 100 μM
(Supplementary Figure S3B-S3C).
We have previously demonstrated the ability
of oncogenic Ras to influence HuR-mediated posttranscriptional regulation of COX-2 and ARE-containing
mRNAs during intestinal cell transformation [32–33]. In
this context, we sought to assess the specificity of MS444 on oncogenic Ras-transformed cells and its effect on
HuR localization. We examined the effects of MS-444 on
non-transformed cells and isogenic variants (RIE-iRAS)
that are transformed by oncogenic Ras. RIE-iRas cells
are RIE-1 containing an IPTG-inducible cDNA of RasV12,
and when cultured in the presence of IPTG for 24 hr to
induce oncogenic Ras, undergo epithelial-to-mesenchymal
transition (EMT) [33, 34]. Shown in Figure 3C,
immunofluorescence analysis of RIE-iRas cells expressing
oncogenic Ras showed cytoplasmic localization of HuR,
whereas in non-transformed cells HuR is predominantly
nuclear. RIE-iRas cells were then cultured in the presence
and absence of IPTG for 24 hr, after which 10 μM MS444 was added. After 8 hr of MS-444 treatment, HuR
localizalization to the nucleus was detected (Figure 3C).
To determine if Ras-transformed cells exhibited a higher
sensitivity to MS-444, growth assays were performed.
RIE-iRas expressing oncogenic Ras exhibited >13-fold
increased sensitivity to MS-444 with an IC50 of 2.33 μM,
www.impactjournals.com/oncotarget
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Figure 3: MS-444 inhibits HuR cytoplasmic localization. A. HCT116 cells treated with 10μM MS-444 for 6 hr were subjected

to HuR immunofluorescence analysis (shown in green). DAPI (shown in blue) was used to visualize nuclei. B. HCT116 cells were treated
with 10μM MS-444 for the indicated times. Cytoplasmic and whole cell lysates were probed for HuR, along with cytoplasmic α-tubulin and
nuclear Lamin A/C markers. C. RIE-iRas cells were untreated or with 5 mM IPTG for 24 hr to induce oncogenic Ras expression, followed
by 10 μM MS-444 for 8 hr. HuR was detected by immunofluorescence (green) along with DAPI was used to visualize nuclei (merged
images shown). D. RIE-iRas were grown in the presence or absence of 5 mM IPTG for 24 hr and then treated with indicated amounts of
MS-444 for 48 hr. Relative cell survival was performed by MTT assay and is represented as average of 4 independent experiments ± SEM.
E. YAMC and YAMC-Ras cells were grown under non-permissive conditions at 37°C and treated with 10 μM MS-444 for 8 hours. HuR
localization was assayed by immunofluorescence. F. MTT assay of YAMC and YAMC-Ras treated with MS-444 for 48 hr under nonpermissive conditions. Bars = 10 μm.
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Figure 4: MS-444 inhibits COX-2 expression and promotes ARE-containing mRNA trafficking to P-bodies. A. HCA-7 cells

were treated with 12 μM MS-444 or a vehicle control for the indicated times. COX-2 mRNA levels were assayed by qPCR using GAPDH as
a loading control and normalized to non-treated cells. Each value represents an average of triplicates ± SEM. B. HCA-7 cells were with the
indicated concentrations of MS-444 for 8 hr and COX-2 mRNA levels were assayed by qPCR. The data was fitted to a dose-response curve to
determine the IC50 with respect to COX-2 mRNA expression. Each data point represents an average of triplicates ± SEM. C. HCA-7 cells were
treated with the indicated concentrations of MS-444 for 8 hr and COX-2 protein expression was assayed by western blot. Actin was used as a
loading control. D. HCA-7 cells were treated with DMSO (control) or 10 μM MS-444 for 6 hr and RNP-IP of HuR or control IgG was done to
isolate mRNAs bound by HuR. qPCR was used to quantitate COX-2 mRNA levels normalized to IgG control as the average from 3 independent
experiments ± SEM. E. HCT116 cells were transfected with luciferase reporter constructs without the COX-2 3'UTR (LucΔ3'UTR) or fused
to the full-length COX-2 3'UTR and treated with 10 μM MS-444 for 8 hr. Luciferase activity was normalized to total protein activity and is the
average of 3 experiments ± SEM. N.S., not significant. F. Representation of the MS2 system showing the reporter mRNA containing MS2 sites
present upstream of the ARE-containing COX-2 3’UTR bound by YFP-tagged MS2 binding protein, allowing for fluorescent visualization of
the mRNA. HCT116 cells were transfected with the MS2 dual plasmid system using the MS2-COX-2 3’UTR mRNA expression constructs,
along with MS2-YFP and mCherry-tagged Dcp1a to visualize mRNA and P-bodies, respectively. Cells were treated with 10 μM MS-444 for 8 hr
and visualized for P-bodies (red) and MS2-YFP-bound mRNA (pseudo-colored green). Arrowheads indicate representative P-body signal with
boxed areas enlarged on right showing Dcp1a and YFP-MS2 signal. Scale bar = 10 μm. G. Co-localization between the reporter MS2-COX-2
3’UTR and P-bodies is shown as percentage of P-bodies per cell exhibiting co-localization between the MS-2-bound YFP mRNA reporter and
Dcp1a signal ± SEM (n = 10 cells per group).
www.impactjournals.com/oncotarget
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with the reporter construct pMS2-COX-2 3'UTR, which
expressed a chimeric RNA consisting of 12 tandem MS2
RNA hairpins and the COX-2 3'UTR (Figure 4F). Cells
were co-transfected with pMS2-YFP, which expresses
YFP-tagged MS2-binding protein that contains a nuclear
localization signal (NLS), allowing for visualization of the
chimeric MS2-COX-2 3'UTR RNA (as the complex MS2YFP/MS2-COX-2 3'UTR). P-bodies were visualized by
co-transfecting the mCherry-tagged P-body marker Dcp1a
[31]. As shown in Figure 4F (right panels), treatment with
MS-444 for 8 hr did not impact P-body numbers or size,
with approximately 6 P-bodies per cell detected in both
control and MS-444-treated cells (Supplementary Figure
S4B). Due to the presence of the NLS in the MS2-YFP
protein, the majority of MS2-YFP signal appeared nuclear
in both conditions (Figure 4F). In control-treated cells,
MS2-COX-2 3'UTR RNA observed in the cytoplasm
showed limited trafficking to P-bodies with co-localization
occurring only in 23% of P-bodies. By contrast, treatment
with MS-444 enhanced co-localization of MS2-COX-2
3'UTR RNA to Dcp1a signal, with approximately 70%
of the total number of P-bodies per cell showing colocalization with the COX-2 3’UTR reporter (Figure
4F-4G). Control experiments using MS2 RNA lacking
a 3'UTR (MS2-Δ3'UTR) showed no reporter RNA colocalization with Dcp1a in the presence or absence of MS444 (data not shown). These findings indicate that MS444 promotes COX-2 mRNA decay by allowing mRNA
trafficking to P-bodies.

cells with significantly heightened apoptotic index. Based
on cytoplasmic HuR localization supporting enhanced
angiogenic gene expression and tumor angiogenesis
[42, 43], we evaluated the impact of MS-444 on tumor
microvessel density (MVD). HCT116 tumor sections
were immunostained with anti-CD31 antibody to visualize
blood vessels and MVD was determined by counting the
number of blood vessels per field imaged. Mice treated
with MS-444 showed a marked 2- to 3-fold decrease in
MVD (Figure 5D), indicating the anti-angiogenic potential
of MS-444.

MS-444 attenuates tumor COX-2 expression
Based on results shown above, the ability of MS444 to alter COX-2 expression in vivo was determined
using HCA-7 cell xenografts that display elevated COX2 levels and COX-2 dependent tumor growth [12, 44,
45]. Using dosing as described with HCT116 tumors,
IP administration of MS-444 was more effective at
inhibiting HCA-7 tumor growth without any observable
adverse effects (Figure 6A, Supplementary Figure S5B).
Consistent with the ability of MS-444 to inhibit COX-2
expression in HCA-7 cells (Figure 4), IHC analysis of
COX-2 protein levels in HCA-7 xenograft tumors was
attenuated by MS-444 (Figure 6B).
Our in vivo observations indicate that MS-444
impacts the growth of established tumors >100 mm3
(Figure 5A, Figure 6A). To further characterize this
and evaluate alternative MS-444 dosing schedules,
HCA-7 cell xenografts were allowed to form palpable
tumors (approximately 100 mm3) and then treated
intraperitoneally with MS-444 (25 mg/kg bw) every 72 hr
for 15 days followed by a 7-day period during which they
received daily injections of the same dose (Figure 6C).
Under this dosing schedule, no significant change in tumor
volume was observed until daily dosing at day 14 (Figure
6C). Assessment of COX-2 expression was determined
by IP injection of the fluorescently-labeled COX-2 probe
(Fluorocoxib) [46] on day 21. Ex vivo Image analysis of
the freshly excised tumors revealed a significant decrease
in COX-2 protein expression (Figure 6D). COX-2 mRNA
analysis determined by qPCR corroborated these findings
(Figure 6E), indicating that selective small molecule-based
inhibition of HuR functionally impacts tumor COX-2
levels and alters tumor growth potential.

MS-444 inhibition of CRC tumor growth in vivo
Prior examination of MS-444 acute toxicity in rats
showed no lethality at concentrations of 100 mg/kg by
intraperitoneal (IP) administration [41]. To determine
a tolerable dose range for mice, a dose escalation study
over 24 hr period was performed by IP, oral (PO),
and intravenous (IV) administration. For IP and PO
administration, no signs of acute toxicity were observed
up to 100 mg/kg. IV administration was well tolerated up
to 25 mg/kg, with some signs of toxicity (hunched posture
and tremors) observed at 50 mg/kg.
To test the effects of MS-444 on CRC cell growth
in vivo, mice bearing HCT116 cell xenografts received
IP injections of MS-444 (25 mg/kg bw) or vehicle every
48 hr. Over the experiment course, mice did not display
any adverse effects and maintained similar weights
(Supplementary Figure S5A). Anti-tumor effects of
MS-444 were observed with approximately 1.7-fold
reduction in tumor size (Figure 5A). The effects of MS444 to inhibit cytoplasmic HuR localization were also
observed in treated tumors (Figure 5B). To determine
if MS-444 treatment attenuated tumor growth through
enhanced apoptosis, sections were stained for caspase 3
cleavage. Shown in Figure 5C, MS-444 treated tumors
exhibited a higher amount of cleaved caspase 3-positive
www.impactjournals.com/oncotarget

DISCUSSION
Although somatic mutations have been closely
linked to the progression model of CRC tumorigenesis
[47]. CRC tumors have a disproportionate level of
tumor promoting genes expressed that contain AREs
within their 3'UTRs [33], and many of these mRNA
transcripts have been shown to be bound and regulated
by the RNA binding protein HuR [19]. Previous work in
74050
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Figure 5: Inhibition of in vivo tumor growth by MS-444. A. Tumor growth of HCT116 cell implants in nude mice treated with 25

mg/kg MS-444 or vehicle control every 48 hr. Representative tumors excised at day 40 and are shown. *, P ≤ 0.05. B. IHC detection of HuR
in MS-444-treated HCT116 xenograft tumors. Representative tissue sections were examined for HuR expression and counterstained with
hematoxylin. Images were acquired at 20x and 40x magnification. C. IHC detection of cleaved caspase 3. Box plots show the apoptotic index
determined by counting the number of cleaved caspase 3-positive cells per 20x field of view (F.O.V). D. HCT116 xenograft tumors were
analyzed for microvessel density using anti-CD31 antibody to mark blood vessels (upper panels). To facilitate microvessel visualization and
quantification, the positive CD31 signal was transposed onto a mask and depicted in white using ImagePro (lower panels). For each tumor,
4 random images were captured at 40X magnification. Each dot represents an average of all scored fields using 9-10 tumors.

www.impactjournals.com/oncotarget

74051

Oncotarget

our lab demonstrated that cytoplasmic HuR localization
is observed in 76% of colorectal adenomas and 94% of
colorectal adenocarcinomas [12]. Moreover, increased
HuR expression and cytoplasmic localization in tumors
correlate with poor disease prognosis and advanced tumor
staging [12, 48–51]. Thus, there are many data points from
multiple laboratories over various tumor types that HuR is
a strong candidate target in cancer [7, 18, 19, 52]. In this
study, MS444 is used here as a tool compound for proofof-principle for pharmacological HuR inhibition, and that
targeting HuR with MS-444 has anti-tumor activity as a
monotherapy in multiple pre-clinical models for CRC.

Logically, the therapeutic strategies to inhibit HuR,
especially in CRC, would be to: 1) silence expression
levels [53], 2) disrupt the ARE-binding activity which is
mediated through the conserved RNA recognition motifs
(RRM) domains of HuR, and 3) inhibit HuR nuclear to
cytoplasmic translocation. In this study, we explored MS444, originally identified as a HuR inhibitor in a confocal
high-throughput screen of microbial, mycological, and
plant extracts [21], wherein MS-444 was successful in
disrupting binding between HuR and its ARE-containing
mRNA targets. Structurally, HuR consists of twotandem RRM domains, followed by a hinge region and

Figure 6: MS-444 inhibits COX-2 expression in vivo. A. Tumor growth of HCA-7 cell implants in nude mice treated with 25 mg/

kg MS-444 or vehicle control every 48 hr. Representative tumors excised at day 44 and are shown. *, P ≤ 0.05. B. IHC detection of COX-2.
Graph indicates the average immunoreactivity scores (IRS) from stained tumor sections (n=10 tumors). C. Tumor growth of established
HCA-7 tumors in mice treated with 25 mg/kg bw MS-444 or vehicle control by IP for 3 weeks as indicated. *, P ≤ 0.01. D. After 21 days,
mice were injected with 2 mg/kg Fluorocoxib, tumors were excised and imaged to detect COX-2 expression ex vivo. Epi-fluorescence scale
is shown. E. COX-2 mRNA expression of excised tumors was measured by qPCR using GAPDH as a loading control.
www.impactjournals.com/oncotarget
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a third RRM domain. The ARE-binding activity of HuR
is mediated through the conserved RRM1/2 domains
[24–27]. RRM1/2 may also provide an interface for HuR
homodimerization, with each HuR monomer contacting
a single ARE [21, 54]. Thus mechanistically, it was
established that MS-444 binds HuR within its first two
tandem RRM motifs and prevents HuR homodimerization,
preventing HuR from trafficking to the cytoplasm, where
it is known to exert its mRNA-stabilizing function [21].
Based on HuR's ability to support an anti-apoptotic
network through post-transcriptional mechanisms [7,
35], we performed a focused qPCR array of apoptosisrelated genes in MS-444-treated CRC cells. Expression
profiling revealed an increased expression of many proapoptotic markers as a result of MS-444 treatment. Our
data demonstrate that the expression of Fas ligand, a
TNF superfamily member, is significantly increased,
accompanied by elevated expression of caspase 8 and cell
death effectors such as Bax and Bid. Additionally, the TNF
receptor superfamily member 10A (TNFSF10A, Death
receptor 4) was significantly upregulated, suggesting
MS-444 triggers an apoptotic response mediated by
TNF superfamily members and death receptor 4 (Figure
2D). Importantly, DR4 has recently been validated as a
HuR target in another tumor system [55]. These results,
along with previous findings in the field, suggest that
inhibition of HuR (via MS-444 treatment) triggers a
Fas-dependent signaling cascade mediated through
cellular caspases, thereby resulting in cell death. An
important remaining question is whether MS-444’s proapoptotic effect is directly due to the disruption of HuR
target gene regulation. For example, previous studies
have demonstrated that HuR mediates an anti-apoptotic
response by repressing the expression of death receptor 5
(DR5), and now more recently DR4 [36, 55]. Consistent
with these findings, siRNA-mediated knockdown and
MS-444 inhibition of HuR resulted in elevated DR5/
DR4 expression levels, thus promoting apoptosis (Figure
2, Supplementary Figure S1) [35, 36, 55], presumably
by making the receptor more available for targeting and
signaling. Interestingly, apoptosis induction by HuR
knockdown was less robust when compared to MS444 treatment. Prior work has demonstrated that during
caspase-mediated apoptosis, HuR is cleaved to generate
two cleavage products that switch its function from
being a pro-survival factor to a promoter of apoptosis
in response to lethal stress [56–58]. Of note, we did not
detect the induction of HuR caspase-dependent cleavage
when cells are treated with MS-444 (unpublished data
D.A.D and J.R.B), indicating that MS-444 selectively
targets HuR and does not influence other pathways known
to promote HuR cleavage.
Studies have demonstrated that inhibition of HuR
can enhance therapeutic efficacy of certain therapeutic
strategies by inhibiting stressors (e.g., hypoxia, glucose
deprivation, chemotherapies) that induce HuR cytoplasmic
www.impactjournals.com/oncotarget

localization in pancreatic cancer cells [18, 59–61]. Our
findings showing the ability of MS-444 to attenuate CRC
tumor growth in vivo through enhanced apoptosis and
decreased angiogenesis, implicate that selective targeting
of these pathways in combination with MS-444 may
improve the limited inhibition on tumor growth by MS444 as a monotherapy. Further efforts to evaluate these
findings in CRC models as a means to identify clinically
available targeted and cytotoxic therapies that would
synergize with HuR targeted therapy are in progress.
These efforts, along with other modes of HuR inhibition
(i.e., targeted siRNA delivery [53]), being evaluated in
pre-clinical models for: 1) targeting specificity, 2) toxicity
profiles, and 3) therapeutic effects against malignant
phenotypes, will further support the notion that HuR is
a valuable target in CRC and that pharmacological HuR
inhibitors such as MS-444 warrant further investigation.

MATERIALS AND METHODS
Cell culture, reagents and molecular docking
Human colorectal cancer cells SW480, HT-29,
HCT116, and RKO were obtained from the American
Type Culture Collection (ATCC); HCA7 cells were
provided by S. Kirkland (Imperial College, London,
United Kingdom). Cells were maintained in Dulbecco's
modified Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) (Hyclone). Intestinal epithelial
cells lines RIE-1, RIE-iRas, YAMC, and YAMC-Ras were
provided by R. D. Beauchamp (Vanderbilt University
Medical Center, Nashville, TN). RIE-iRas cells were
cultured as described [34] using 5 mM isopropyl β-D-1thiogalactopyranoside (IPTG) to induce the expression
of oncogenic RasV12 cDNA. Conditionally immortalized
colonocytes YAMC and YAMC-Ras (YAMC cells
overexpressing the v-Ha-Ras oncogene) cells were
maintained under permissive conditions as described [39]
at 33°C in RPMI-1640 media containing 25 mM HEPES
and 2 mM L-glutamine (Invitrogen) and supplemented
with 5% FBS, insulin, transferrin, and selenium (ITS)
(Sigma-Aldrich), and 5 U/ml of murine IFN-γ (Roche).
Experiments were performed with cells at non-permissive
conditions at 37°C without IFN-γ in the growth medium.
MS-444 was obtained from Novartis Institutes for
Biomedical Research (Basel, Switzerland) and solubilized
in DMSO using an extinction coefficient of 2,200 M-1cm-1
at 328 nm.
Molecular docking was performed using the X-ray
crystal structure of two methylated tandem RRM domains
(RRM1/2) of HuR in their RNA-free form (PDB ID:
4EGL) [28]. MS-444 ligand was energy minimized and
partial charges were added using PRODRG algorithms
[62] and docked using Auto-Dock Vina software [63]. The
Auto-Dock Tools graphical user interface [64] was used
to add polar hydrogens and partial charges to 4EGL using
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Kollman United charges. Atomic solvation parameters
and fragment volumes were assigned using the ADDSOL
subroutine. The grid map was calculated using the
auxiliary program Autogrid3. Grid maps of 120x120x120
points centered on the active site of the ligand with
0.375 A° spacing were calculated for each atom types
found on the adducts. Lamarckian Genetic Algorithm
(LGA) was selected for ligand conformational search.
The Genetic Algorithm (GA) population size was set to
150, the maximum number of GA energy evaluations as
2500000, GA mutation rate as 0.02, GA crossover rate as
0.8 and GA docking runs was set as 100. The resulting
docking conformations were clustered into families of
similar conformation, with root mean square deviation
(RMSD) clustering tolerance as 1.0 A°. As a rule, the
lowest docking energy conformations were included in the
largest cluster. Flexible torsion in the ligands was assigned
with AUTOTORS, an auxiliary module for Auto-Dock
Tools. The ligand was docked to obtain the best binding
conformation.

and COX-2 (160126, Cayman Chemical) at a dilution
of 1:1000 for 16 hours at 4°C. Caspase 3 cleavage was
detected using rabbit polyclonal anti-Caspase 3 (9662,
Cell Signaling) at a dilution of 1:1000 for 16 hr at 4°C.
Membranes were stripped and re-probed using β-actin
antibody (Clone C4; MP Biomedicals). Cytoplasmic
lysates were obtained using NE-PER cytoplasmic
extraction reagent (Thermo Scientific) using α-tubulin
(322500, 1:20,000 dilution, Invitrogen) and Lamin
A/C (2032S, 1:2,000 dilution, Cell Signaling) as
cytoplasmic and nuclear loading controls, respectively.
Detection and quantitation of blots were carried out as
described [10].

RNA analysis
Total RNA was extracted using Trizol reagent
(Invitrogen). cDNA synthesis was performed using 1 μg
of total RNA in combination with oligo(dT) and ImpromII reverse transcriptase (Promega). qPCR analysis was
performed as described [12] using the 7300 PCR Assay
System with TaqMan probes for COX-2 (PTGS2) and
GAPDH (Applied Biosystems). GAPDH was used as
a control for normalization. Detection of apoptosisassociated mRNAs was accomplished using Apoptosis
PCR Array PAHS-012Z (SA Biosciences/Qiagen) and
qPCR was performed according to the manufacturer’s
protocol using SYBR green PCR master mix (Applied
Biosystems). Fold change in mRNA expression levels was
normalized to the cycle threshold (Ct) using non-treated
cells and analyzed by the ΔΔCt method.

MS-444 sensitivity assay
Cells were seeded at subconfluent levels (<50%
confluence) in 96-well tissue culture plates and treated
with increasing concentrations of MS-444 [21] for 48
hours at 37°C. Cell survival was assayed using the MTTbased cell growth determination kit (Sigma-Aldrich)
as previously described [3]. Relative cell survival was
calculated as percentage relative to DMSO vehicle-treated
controls. A dose-response curve was fitted to the data using
the software KaleidaGraph 4.0 (Synergy), from which the
half-maximal inhibitory concentration (IC50) was derived
and represented as a mean of 4 independent experiments
± standard error of the mean (SEM).

Ribonucleoprotein immunoprecipitations
Immunoprecipitation (IP) of ribonucleoprotein
complexes (RNP-IP) was done as described [6] using
HCA-7 cells grown on 100 mm dishes treated with
either vehicle DMSO or 10 μM MS-444 for 6 hr. Prior
to harvesting cells, 40 μl of Protein A/G beads (sc2003, Santa Cruz Biotechnology) were coated with 20
μg of rabbit anti-HuR (3A2, Cat # sc-5261, Santa Cruz
Biotechnology) or control IgG antibody overnight at
4°C. Beads were washed in NT2 buffer (50 mM Tris-HCl
pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.05% NP-40) and
incubated with equal amounts (250 μg) of cytoplasmic
lysates obtained from cells lysed in 200 μl polysome
lysis buffer (20 mM Tris-HCl pH 7.6, 5 mM MgCl2, 150
mM NaCl, 1 mM DTT, 0.5% NP-40) containing 100
U/ml RNase inhibitor (Ambion) and protease inhibitor
cocktail (Sigma-Aldrich) and incubated overnight at
4°C with HuR- or control-IgG coated beads. Reactions
were washed 5X with NT2 buffer and total RNA was
isolated from immunoprecipitates using 1 mL TRIzol
per IP reaction and then used for cDNA synthesis.
Analysis of COX-2 (PTGS2) mRNA was done by qPCR
as described above.

Annexin V staining and flow cytometry
HCT116 and RIE-1 cells treated with 10 μM MS444 for 48 hours were subjected to Annexin V staining and
flow cytometry per manufacturer’s protocol (ThermoFisherMolecular Probes). 1x106 cells were resuspended in Annexin
V binding buffer and incubated with 5 μL Annexin V-PE and
5 μL propidium iodide for 15 minutes in the dark. Cells were
subjected to flow cytometry using the BD Accuri C6 flow
cytometer. The collected data was subjected to compensation
analysis by adjusting the gating and virtual voltage in the BD
Accuri C6 software and graphically represented as means
of 3 independent experiments. Cells treated with 5 μg/ml
cycloheximide (Chx) (Sigma-Aldrich) and 10 ng/ml TNF-α
(R&D Systems) for 8 hr were used as positive controls.

Western blotting
Western blots were performed as described [12]
using antibodies against HuR (clone 3A2, Santa Cruz
Biotechnology) at a dilution of 1:20,000 for 1 hr at RT
www.impactjournals.com/oncotarget
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DNA transfections

Immunohistochemistry (IHC)

Luciferase reporter constructs containing the COX2 3’UTR (Luc+COX-2 3'UTR) or control (LucΔ3'UTR)
were transfected as previously described [31]. Cells were
transfected for 24 hr, then treated with MS-444 for 8 hr
before being lysed in reporter lysis buffer and assayed
using the Luciferase Assay System (Promega, Madison,
WI). Reporter gene activities were normalized to total
protein; all results represent the average of triplicate
experiments.
The MS2-based plasmids pcDNA-MS2-YFP and
pMS2-COX-2 3'UTR used for fluorescent visualization
of RNA, and the P-body marker mCherry-tagged Dcp1a
(pmCherry-Dcp1a) have been previously described [31,
40]. The MS2 plasmids were transiently co-transfected
with pmCherry-Dcp1a into HCT116 cells using
Lipofectamine Plus for 24 hr and the cells were treated
with 10 μM MS-444 for 8 hr. Cells were harvested in
2% paraformaldehyde and prepared for fluorescence
microscopy.

IHC was performed using formalin-fixed,
paraffin-embedded (FFPE) tumors sectioned at 4 μm
with monoclonal anti-HuR antibody (19F12; Molecular
Probes) at 1:1250, polyclonal anti-cleaved caspase 3
(Asp175) antibody (#9661, Cell Signaling Technologies)
at 1:1000, and polyclonal anti-COX-2 (160126;
Cayman Chemical) at 1:400 dilutions. Staining and
immunoreactivity scoring was performed as described
previously [12, 65].

Microvessel density analysis
Tumor microvessels were detected by IHC ofFFPE
tumors using a polyclonal antibody to CD31 (ab28364;
Abcam) at a dilution of 1:500 for 1 hr at RT in primary
antibody diluent (Dako). After washing in Tris-buffered
saline containing 0.05% Tween-20 (TBS-T), slides were
incubated with biotinylated anti-rabbit labeled polymer
(Dako). IHC was visualized using DAB peroxidase
substrate kit (Dako) and counterstained with hematoxylin
(Sigma-Aldrich). The area of tumor microvessels was
quantitatively measured using the ImagePro Plus 4.5
software (Media Cybernetics) as previously described
[66]. Tumor section images were imported into the
ImagePro Plus software, where the CD31-positive staining
was selected using the color selection function. Positive
staining pixels were measured using the area/density
(intensity) measurement function and represented as
microvessel density.

Immunofluorescence
Cells grown on coverslips were washed twice
with PBS containing 10 mM glycine, fixed in 2%
paraformaldehyde for 15 min at RT, and permeabilized
with 0.02% Triton X-100 (Sigma-Aldrich) in PBS.
Cells were blocked with 5% normal goat serum in PBS
containing 1% IgG-free BSA (Jackson Immunoresearch)
and incubated with primary antibody overnight at 4°C
diluted in blocking solution. HuR was detectedwith
anti-HuR monoclonal primary antibody (3A2, 1:200
dilution; Santa Cruz Biotechnology) for 1 hr at RT.
Secondary antibody incubation was done for 1 hr at
RT using FITC-conjugated anti-mouse IgG (1:100
dilution) or Alexa488-conjugated anti-mouse IgG (1:500
dilution; Invitrogen). Cells were counter-stained with
DAPI to visualize nuclei. Fluorescence microscopy
and image analysis was accomplished as described [31,
61]. Detection of P-bodies and assessment of P-body
co-localization with MS2-YFP was accomplished as
described [31].

Ex Vivo imaging of COX-2
Athymic nude (Nu/Nu) mice bearing HCA-7
xenografts were established as described above. When
palpable tumors (~100 mm3) were observed, mice were
treated with MS-444 or vehicle control as indicated.
COX-2 protein expression was visualized ex vivo by IP
injection of 2 mg/kg of Fluorocoxib (Xenolght Rediject
Fluorescent COX-2 Probe, Caliper Life Sciences) for
3 hr. Mice were euthanized and excised tumors were
imaged in an IVIS platform (Caliper Life Sciences) with
the following settings: 570 excitation, 620 emission,
F-1 Stop, epifluorescence. Following visualization, the
tumors were snap-frozen and processed for RNA and
protein analysis.

Xenograft tumor growth
Athymic nude (Nu/Nu) mice were purchased
from Harlan Laboratories and maintained under sterile
conditions in cage micro-isolators according to approved
IACUC guidelines. HCT116 (2 x 106 cells) and HCA-7
(2.5 x 106) cells resuspended in PBS were injected into
the dorsal subcutaneous tissue. Mice (n=5 per group)
received intraperitoneal (IP) injections of MS-444 (25 mg/
kg) dissolved in PBS/5% N-Methyl Pyrrolidine (NMP)
(Sigma-Aldrich) or vehicle control every 48 hr. Tumor
growth was assayed as described [3].

www.impactjournals.com/oncotarget

Statistical analysis
Statistical analyses were performed using GraphPad
Prism (GraphPad Software). The data are expressed as the
mean of three independent experiments ± S.E.M. Student’s
t-test was used to determine significant differences.
P-values less than 0.05 were considered statistically
significant.
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